Wall Street brokerages forecast that Aurora Cannabis Inc. (NYSE:ACB) will announce earnings of ($0.16) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Aurora Cannabis’ earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.14). Aurora Cannabis posted earnings per share of ($0.74) in the same quarter last year, which indicates a positive year-over-year growth rate of 78.4%. The business is expected to issue its next earnings results on Thursday, May 13th.
According to Zacks, analysts expect that Aurora Cannabis will report full year earnings of ($2.39) per share for the current year, with EPS estimates ranging from ($2.76) to ($1.83). For the next financial year, analysts expect that the company will report earnings of ($0.51) per share, with EPS estimates ranging from ($0.75) to ($0.29). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Aurora Cannabis.
Aurora Cannabis (NYSE:ACB) last posted its quarterly earnings data on Thursday, February 11th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). Aurora Cannabis had a negative return on equity of 16.32% and a negative net margin of 1,238.94%. The company had revenue of $51.93 million for the quarter, compared to analysts’ expectations of $54.66 million.
Several equities analysts recently commented on ACB shares. BMO Capital Markets lowered Aurora Cannabis from a “market perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a report on Thursday, December 17th. MKM Partners lowered Aurora Cannabis from a “neutral” rating to a “sell” rating in a report on Friday, February 12th. Needham & Company LLC lowered Aurora Cannabis from a “hold” rating to an “underperform” rating in a report on Friday, February 12th. Desjardins downgraded shares of Aurora Cannabis from a “hold” rating to a “sell” rating in a research note on Friday, February 12th. Finally, Cantor Fitzgerald upped their price objective on shares of Aurora Cannabis from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Friday, February 12th. Seven analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $11.47.
A number of large investors have recently made changes to their positions in ACB. ETF Managers Group LLC lifted its position in Aurora Cannabis by 46.9% in the fourth quarter. ETF Managers Group LLC now owns 6,785,656 shares of the company’s stock valued at $56,389,000 after purchasing an additional 2,167,593 shares during the period. JPMorgan Chase & Co. lifted its position in Aurora Cannabis by 455.6% in the third quarter. JPMorgan Chase & Co. now owns 785,141 shares of the company’s stock valued at $6,823,000 after purchasing an additional 643,833 shares during the period. Morgan Stanley increased its holdings in Aurora Cannabis by 59.2% in the third quarter. Morgan Stanley now owns 1,123,802 shares of the company’s stock valued at $5,225,000 after buying an additional 418,049 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in Aurora Cannabis in the third quarter valued at about $1,198,000. Finally, CIBC Asset Management Inc increased its holdings in Aurora Cannabis by 357.0% in the fourth quarter. CIBC Asset Management Inc now owns 308,780 shares of the company’s stock valued at $2,565,000 after buying an additional 241,218 shares in the last quarter. Hedge funds and other institutional investors own 11.86% of the company’s stock.
NYSE:ACB traded up $0.14 during trading hours on Friday, hitting $10.14. The company’s stock had a trading volume of 7,397,981 shares, compared to its average volume of 25,729,779. The stock has a market capitalization of $2.01 billion, a P/E ratio of -0.41 and a beta of 3.44. The stock has a fifty day moving average of $11.72 and a 200-day moving average of $8.82. The company has a current ratio of 1.88, a quick ratio of 1.07 and a debt-to-equity ratio of 0.17. Aurora Cannabis has a 52-week low of $3.71 and a 52-week high of $19.68.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Read More: What is the G-20?
Get a free copy of the Zacks research report on Aurora Cannabis (ACB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.
Recent Comments